Abstract:
Summary
During 6 month 15 patients with BPH were treated with Prostamo®Uno, 320mg, daily. In this trial
patients were assessed pre- and post- treatment with International Prostate Symptom Score (IPSS),
the Quality of Life (QOL) and volume of residual urine appreciated ecographically. The analysis of
our data shows decrease in IPSS score, QOL and volume of residual urine with in 53,4 %, 57,5% and
48,7% respectively. Prostamo®Uno is one of election drug in conservative treatment of BPH.
